Pharmaceutical - North America


Current filters:

North America

Popular Filters

7066 to 7090 of 7215 results

Shire to buy regenerative medicines firm Advanced BioHealing for $750 million


Ireland-headquartered biopharmaceutical firm Shire (LSE: SHP) - best known for its attention-deficit…

Advanced BioHealingDermagraftMergers & AcquisitionsPharmaceuticalShire

Pfizer files for US and Japanese approval of crizotinib for NSCLC


US drug behemoth Pfizer (NYSE: PFE) says that its New Drug Application for crizotinib, an oral first-in-class…

Asia-PacificcrizotinibNorth AmericaOncologyPfizerPharmaceuticalRegulation

Turkish pharma - pushed to the limit - calling off some investments


Times are hard for pharmaceutical companies in Turkey, particularly research-based ones, who are left…

EuropeFinancialMarkets & MarketingPharmaceuticalPricing

Dr Reddy’s gains Indian rights to Oceana’s Deflux


Privately-held US company Oceana Therapeutics, which is focused on acquiring, developing and commercializing…

DefluxDr Reddy's LaboratoriesLicensingOceana TherapeuticsPharmaceutical

Australia’s TGA approves Biogen’s Fampyra to improve MS patients walking ability


The Australian Therapeutic Goods Administration (TGA) has granted approval for USA-based Biogen Idec’s…

AmpyraAsia-PacificBiogen IdecFampyraNeurologicalPharmaceuticalRegulation

Histogenics acquires ProChon Biotech in stock deal


Massachusetts, USA-based Histogenics Corp, a privately held regenerative medicine company, says that…

Anti-Arthritics/RheumaticsHistogenicsMergers & AcquisitionsPharmaceuticalProChon Biotech

Osteoarthritis pain therapeutics market set to show slow growth until 2017


The global osteoarthritis pain therapeutics market was valued at $4.9 billion in 2010, and is forecast…

Anti-Arthritics/RheumaticsMarkets & MarketingPharmaceutical

Amylin sues Eli Lilly, alleging anti-competitive activity


San Diego, USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) has filed a law suit against drug major Eli…

AmylinBoehringer IngelheimByettaDiabetesEli LillyLegallinagliptinPharmaceuticalTradjenta

Glenmark sells rights to Crohn’s drug to Sanofi for up to $613 million


In a second licensing deal between the companies, Indian drugmaker Glenmark Pharmaceuticals, through…

Anti-Arthritics/RheumaticsGlenmark PharmaceuticalsLicensingPharmaceuticalSanofi

Alimera resubmits eye drug Iluvien to US regulator


USA-based Alimera Sciences (Nasdaq: ALIM) says that it has resubmitted its New Drug Application for Iluvien…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Mitsui to acquire Mercian pharma and chemicals unit


Japan’s Mitsui & Co said recently that it has decided to acquire a 100% stake in MBS Co Ltd, a…

MercianMergers & AcquisitionsMitsui & CoPharmaceutical

ABPI calls on UK govt to embrace innovation in medicines


Faster uptake of new technologies and innovative new medicines is vital to helping the government deliver…


Positive Ph III results with InterMune’s pirfenidone


Phase III trials, demonstrating that treatment with US biotech firm InterMune’s (Nasdaq: ITMN) pirfenidone,…

BiotechnologyInterMunePharmaceuticalpirfenidoneRare diseasesResearch

Low-dose sorafenib may improve therapy for head and neck cancer, Ohio researchers find


Adding low doses of the targeted agent sorafenib (German drug major Bayer and Onyx’ kidney and liver…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Novel ACR hybrid score in RA applied to study with UCB’s Cimzia


The ACR hybrid score, a new measure of response to rheumatoid arthritis (RA) treatment recently developed…


US FDA clears first hep C drug in a decade, Merck & Co’s Victrelis


In much awaited, though largely expected news, the US Food and Drug Administration on Friday approved…

Anti-viralsboceprevirMerck & CoNorth AmericaPharmaceuticalRegulationtelaprevirVertexVictrelis

US Medicare likely to run out of funds in 2024; Congressional Affordable Medicines Caucus


The US Trustees of the Social Security and Medicare trust funds report on the current and projected financial…

GenericsHealthcareNorth AmericaPharmaceuticalPoliticsPricing

Over 850 drugs in development for diseases that disproportionately strike women, says PhRMA


Medical researchers are making unprecedented progress into understanding why women suffer disproportionately…


Ever Neuro Pharma may build production plant for Cerebrolysin in Russia


Austrian pharmaceutical producer Ever Neuro Pharma is considering building a plant for the production…

CerebrolysinEuropeEver Neuro PharmaFinancialNeurologicalPharmaceutical

7066 to 7090 of 7215 results

Back to top